Decode the challenges, unlock the solutions: bioanalysis for oligonucleotide drugs
The development of oligonucleotide-based therapeutics has recently attracted extensive attention due to their eminent potential. Oligonucleotide therapies have many advantages, including ease of design, a wide range of targets and high specificity. However, the chemical characteristics of oligonucleotides pose a significant challenge for bioanalysis. In addition, the immunogenicity and immunotoxicity potential of oligonucleotides are of concern in preclinical and clinical trials. To better facilitate oligonucleotide drug development, we share some bioanalytical strategies and case studies regarding the mitigation of these challenges.
